Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them,
use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions
and methods for the treatment and/or prevention of disorders and diseases wherein
an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders
such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
